Investors Relation

Tikva Allocell is a pre-clinical stage biotechnology company focused on Highly Differentiated, Enhanced, Allogeneic EBV Specific T cell platform, targeting difficult to treat, unmet medical patient population. Founded and led by a team with significant experience in cell therapy, we are developing a pipeline of “off-the-shelf” CAR T cell candidates with the goal of delivering readily available cell therapy, more reliably, and at greater scale to more patients.

Tikva Allocell is excited to work with investors as we continue to raise additional funding to unlock the potential of our IP protected ALLO EBVST platform.